Medicina (May 2023)

Longitudinal Assessment of Multimorbidity Medication Patterns among Smokers in the COPDGene Cohort

  • Yisha Li,
  • Sarah J. Schmiege,
  • Heather Anderson,
  • Nicole E. Richmond,
  • Kendra A. Young,
  • John E. Hokanson,
  • Stephen I. Rennard,
  • Tessa L. Crume,
  • Erin Austin,
  • Katherine A. Pratte,
  • Rebecca Conway,
  • Gregory L. Kinney

DOI
https://doi.org/10.3390/medicina59050976
Journal volume & issue
Vol. 59, no. 5
p. 976

Abstract

Read online

Background and objectives: Chronic obstructive pulmonary disease (COPD) is usually comorbid with other chronic diseases. We aimed to assess the multimorbidity medication patterns and explore if the patterns are similar for phase 1 (P1) and 5-year follow-up phase 2 (P2) in the COPDGene cohort. Materials and Methods: A total of 5564 out of 10,198 smokers from the COPDGene cohort who completed 2 visits, P1 and P2 visits, with complete medication use history were included in the study. We conducted latent class analysis (LCA) among the 27 categories of chronic disease medications, excluding COPD treatments and cancer medications at P1 and P2 separately. The best number of LCA classes was determined through both statistical fit and interpretation of the patterns. Results: We found four classes of medication patterns at both phases. LCA showed that both phases shared similar characteristics in their medication patterns: LC0: low medication; LC1: hypertension (HTN) or cardiovascular disease (CVD)+high cholesterol (Hychol) medication predominant; LC2: HTN/CVD+type 2 diabetes (T2D) +Hychol medication predominant; LC3: Hychol medication predominant. Conclusions: We found similar multimorbidity medication patterns among smokers at P1 and P2 in the COPDGene cohort, which provides an understanding of how multimorbidity medication clustered and how different chronic diseases combine in smokers.

Keywords